Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU

NCT00628862 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

613

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Formoterol Turbuhaler® 4.5mg
DRUG: Formoterol Turbuhaler® 9 mg
DRUG: Turbuhaler® placebo

Sponsor

AstraZeneca